. 2017 Nov 15;8(65):108989–108999. doi: 10.18632/oncotarget.22480

Table 3. Crude and adjusted hazard ratio (HR) for the development of cancer among stroke and control groups.

Cancer type	Stroke N=17161		Control N=68644		Crude HR (95% CI)	Adjusted HR^a (95% CI)
Cancer type	N	%	N	%	Crude HR (95% CI)	Adjusted HR^a (95% CI)
All (140–192)	1408	8.20	6763	9.85	0.93 (0.88-0.98)^*	0.79 (0.74-0.84)^*
Head and neck (140–149)	76	0.44	334	0.49	1.00 (0.78-1.28)	0.89 (0.67-1.18)
Digestive (150–159, 179, 185-189)	833	4.85	3979	5.80	0.93 (0.86-1.00)	0.75 (0.70-0.82)^*
Respiratory (160–165)	235	1.37	1167	1.70	0.89 (0.77-1.02)	0.85 (0.73-0.99)^*
Bone and Skin (170-173, 176)	43	0.25	233	0.34	0.81 (0.59-1.13)	0.69 (0.48-0.98)^*
Brain cancer (191, 192.0, 192.1)	27	0.16	47	0.07	2.48 (1.55-3.98)^*	3.09 (1.80-5.30)^*
Others	194	1.13	1003	1.46	0.85 (0.73-0.99)^*	0.74 (0.63-0.89)^*

^aAdjusted by age groups, gender and comorbidities.

^*P-value<0.05.